THANK YOU FOR SUBSCRIBING
Pharma Tech Outlook | Monday, March 02, 2020
Over the past few years, advancements in biotechnology capabilities have made it possible for scientists and researchers to engineer biological molecules for medical purposes, for instance, recombinant hormones, mAbs, vaccines, and more.
FREMONT, CA: Typically, biotherapeutics are proteins or polypeptides of more than 40 amino acids whose active components are built through biotechnology.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
In the case of traditional small molecule drugs, it is vital to characterize biotherapeutics completely before they are marketed for ensuring patient safety. Indeed, this is vital for protein-based therapies since these possess the capability to elicit an immune response.
The[vendor_logo_first] requirement for obtaining in-depth structural and compositional knowledge of intricate biopharmaceutical has lead to increased demands on bioanalytical capabilities. Indeed, it has accelerated the development and enhancement of various techniques for assessing proteins and determining immunogenicity.
Evaluation of immunogenicity
The multiple opportunities for structural heterogeneity in recombinant proteins have led to the risk of immunogenicity. Therefore, it is essential that antibodies against a biotherapeutic are reliably identified and differentiated from other antibodies. Besides, it is vital to completely characterize the specific pattern of post-translational alterations on a biotherapeutic so that immunogenic potential can be analyzed earlier in the development process.
In this case, intact liquid chromatography-mass spectrometry (LC-MS) methods are essential tools for analyzing structural modifications, like glycation of proteins. Mass spectrometry imaging (MSI) is not only capable of detecting a broad range of biomolecules but can also map out their spatial distributions simultaneously.
Biotherapeutic products’ characterization
For detailed characterization of biopharmaceuticals, ultra-high-performance liquid chromatography (UHPLC), coupled with its good resolution speed, has proven to be an important tool as it possesses powerful separation capabilities.
Multiple UHPLC methods are utilized in combination with a detection capability, like UV, or light scattering, and extra structural information can be obtained by using mass spectrometry. A multidimensional approach like this helps in increasing the potential sensitivity and makes it possible to characterize more intricate proteins.
However, in order to obtain complete separation of biotherapeutics, a complicated and arduous method development process is often required to search for the optimal UHPLC configuration.
Doubtlessly, there has already been a lot of advancements in biotherapeutics. Yet more is to come.
More in News